This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
n6	http://dx.doi.org/10.2337/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
p	http://www.wikidata.org/prop/
wikibase	http://wikiba.se/ontology#
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q51280414

rdf:type

wikibase:Item

schema:description

научни чланак scienca artikolo 2016年学术文章 2016年學術文章 2016 nî lūn-bûn artigo científico 2016年学术文章 scientific article published on 15 August 2016 2016년 논문 artikel ilmiah مقالة علمية نشرت في 15 أغسطس 2016 bài báo khoa học article scientific ১৫ আগস্ট ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articol științific מאמר מדעי επιστημονικό άρθρο artigo científico 2016年學術文章 artículo científico publicado en 2016 2016年の論文 scientific article published on 15 August 2016 2016年学术文章 vetenskaplig artikel наукова стаття, опублікована в серпні 2016 vedecký článok bilimsel makale 2016年學術文章 мақолаи илмӣ wissenschaftlicher Artikel tudományos cikk artículu científicu บทความทางวิทยาศาสตร์ tieteellinen artikkeli scientific article published on 15 August 2016 artikull shkencor artykuł naukowy wetenschappelijk artikel videnskabelig artikel naučni članak vitskapeleg artikkel 2016年学术文章 научна статия artigo científico 2016年学术文章 teaduslik artikkel 2016年學術文章 2016年學術文章 სამეცნიერო სტატია научни чланак articolo scientifico vitenskapelig artikkel vědecký článek artikulong pang-agham 2016年学术文章 научная статья article científic article scientifique

p:P577

wds:Q51280414-CAD4E20F-097E-4D68-B118-87BBA3C976E8

wdt:P577

2016-08-15T00:00:00Z

p:P407

wds:Q51280414-84F12C07-6E9B-450B-8594-7BF7887D6E5B

wdt:P407

wd:Q1860

p:P2093

wds:Q51280414-B7E9D688-3156-49C5-9580-30A7615A6EB2 wds:Q51280414-C1B6C5B4-ADF2-4E77-B8CF-8C1525B5BEC4 wds:Q51280414-D3686E86-D59E-445C-B62C-3F5E55DDA947 wds:Q51280414-C3EF0AA2-B030-4233-99C1-A6E79E0B5585 wds:Q51280414-DB0B4D57-0E69-4A55-BEEE-717CBBB07B19 wds:Q51280414-71909368-3025-4889-983D-A264B4F7C53A wds:Q51280414-4C8057B8-170F-4529-9784-BC31B3801980 wds:Q51280414-71DBAF68-CF1F-4AE7-8DF5-3CCBF49CEA4B

wdt:P2093

Tianyue Zhou Xi Cheng PierMarco Piatti Ronnie Aronson Pierre Serusclat Elisabeth Niemoeller Elisabeth Souhami LixiLan-O Trial Investigators

rdfs:label

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

skos:prefLabel

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

schema:name

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

p:P50

wds:Q51280414-D8858775-5836-406E-9D4A-C24DD03D47B3 wds:Q51280414-8F7B86B4-1716-4388-AFA8-5A7C67B647E8 wds:Q51280414-980458E4-478E-4C06-B86B-902AEC830363 wds:Q51280414-288A137A-A732-49E4-84C7-C974A914D26D

wdt:P50

wd:Q90148608 wd:Q60996888 wd:Q51732471 wd:Q37373997

p:P1476

wds:Q51280414-D56ED899-6422-494F-83EC-5B01628DEC5D

wdt:P1476

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

p:P304

wds:Q51280414-CB3FDD6F-8E1E-4AD5-AF5D-5439B875AC7D

wdt:P304

2026-2035

p:P31

wds:Q51280414-03E9D7AD-8C50-4FB8-B48D-A2A24521A4EE

wdt:P31

wd:Q13442814

p:P921

wds:Q51280414-08FC4E15-4F68-4F2D-BAEC-F0FAF21420AB wds:Q51280414-1AC9951B-56CA-41B9-A34A-C156075B019B

wdt:P921

wd:Q3025883 wd:Q417317

p:P698

wds:Q51280414-F236418D-2AF0-44A8-B2D5-46E36C45DEE2

wdtn:P698

n12:27527848

wdt:P698

27527848

p:P1433

wds:Q51280414-1BF44F17-A2F0-4890-A55B-5638C13CAD40

wdt:P1433

wd:Q5270111

p:P433

wds:Q51280414-795D7B45-F31E-42FD-9B8A-A21E8CF13F5E

p:P478

wds:Q51280414-7A2C2898-A60A-4715-BA8A-D72B9249D6DE

wdt:P433

11

wdt:P478

39

p:P356

wds:Q51280414-39A24848-3BFA-4556-80F8-FED0D0A53DDC

wdtn:P356

n6:DC16-0917

wdt:P356

10.2337/DC16-0917

p:P2507

wds:Q51280414-5CC038DF-F435-4765-9B7B-994569ECBDDE

wdt:P2507

wd:Q53777921